title: [The predictive factors of good glycaemic control in Chinese patients receiving biphasic insulin as part 30: a subgroup analyses from the A1 chieve study].
abstract: OBJECTIVE
  To identify the baseline factors associated with achievement of glycosylated haemoglobin A1c (HbA1c) < 7.0% in Chinese patients receiving biphasic insulin as part 30 (BIAsp 30), who were previously inadequately controlled with oral anti-diabetic drugs (OADs).
  
  
  METHODS
  A1 chieve was a multinational, prospective, open-label, 24-week non-interventional study in patients with type 2 diabetes initiating insulin analogues in 28 countries. The patients were enrolled to take BIAsp 30 according to physician's clinical judgments, who was also responsible for the treatment regimen and dosage adjustment. Primary safety endpoints were the incidence of serious drug adverse reactions (SADRs) including serious hypoglycaemia. Major efficacy endpoints were change in HbA1c, fasting plasma glucose (FPG), 2h post-prandial plasma glucose (2 hPG) from baseline. Relationships between baseline predictive baseline factors and achievement of HbA1c < 7.0% after treatment were examined using multivariate analysis.
  
  
  RESULTS
  In China, 4 100 patients initiated BIAsp 30 [54.2% males, age (56.2 ± 13.6) years]. No SADRs were reported. Mean HbA1c was reduced from (9.3 ± 2.1)% to (7.0 ± 1.0)%; FPG was reduced from (10.2 ± 3.3) mmol/L to (6.8 ± 1.3) mmol/L. Changes in 2 hPG after breakfast, lunch and dinner were (-5.6 ± 4.7), (-4.9 ± 4.3) and (-4.2 ± 4.1) mmol/L, respectively (all P < 0.001). The proportion of patients achieving HbA1c < 7.0% increased from 9.7% at baseline to 54.2% at week 24. Multivariate analysis revealed a negative relationship between baseline HbA1c, FPG, 2 hPG and HbA1c < 7.0% after treatment.
  
  
  CONCLUSIONS
  In the Chinese subgroup of the A1 chieve study, lower baseline HbA1c, FPG, 2 hPG were predictive factors for achieving HbA1c < 7.0% after 24-week treatment of BIAsp 30, indicating that the earlier initiation of BIAsp 30 in patients poorly controlled with OADs, the more helpful for them to achieve treatment target.
authors.forename: Jing
authors.initials: J
authors.lastname: Hong
authors.forename: Minxiang
authors.initials: M
authors.lastname: Lei
authors.forename: Baocheng
authors.initials: B
authors.lastname: Chang
authors.forename: Zhengnan
authors.initials: Z
authors.lastname: Gao
authors.forename: Zhanjian
authors.initials: Z
authors.lastname: Wang
authors.forename: Xiujuan
authors.initials: X
authors.lastname: Zhang
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Zhuang
authors.forename: Bing
authors.initials: B
authors.lastname: Chen
authors.forename: Mingzhi
authors.initials: M
authors.lastname: Xu
authors.affiliation: Department of Endocrinology, China-Japan Friendship Hospital, Beijing 100029, China; Email: ywying_1010@163.com.
authors.forename: Wenying
authors.initials: W
authors.lastname: Yang
mesh_terms: D000284:Administration, Oral; D044466:Asian People; D061265:Biphasic Insulins / Q000008:administration & dosage* / Q000627:therapeutic use; D001786:Blood Glucose / Q000187:drug effects; D002681:China; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000208:ethnology; D006442:Glycated Hemoglobin; D006801:Humans; D007003:Hypoglycemia; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D061267:Insulin Aspart; D007336:Insulin, Isophane; D008297:Male; D011446:Prospective Studies
chemical_list: D061265:Biphasic Insulins; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D061267:Insulin Aspart; D007336:Insulin, Isophane